surfac
protein
human
immunodefici
env
fusion
protein
env
heavili
glycosyl
glycan
compos
half
mass
matur
env
fulllength
cleav
proteas
remain
associ
form
env
heterodim
three
heterodim
form
trimer
spike
approxim
spike
decor
surfac
viru
major
glycan
present
viru
underprocess
nlink
high
mannos
high
densiti
glycosyl
site
prevent
process
step
glycan
enzym
golgi
apparatu
chang
glycosyl
pattern
alter
receptor
bind
infect
viru
well
suscept
antibodi
addit
high
mutat
rate
result
inconsist
level
glycosyl
exampl
transmitterfound
virus
gener
lower
number
nlink
glycosyl
site
chronic
virus
appear
infecti
major
effort
undertaken
understand
role
glycan
respect
broadli
neutral
antibodi
bnab
env
protein
antibodi
directli
interact
glycan
wellknown
bnab
exclus
recogn
glycosyl
pattern
bnab
interact
glycan
amino
acid
sequenc
structur
featur
long
loop
penetr
glycan
shield
bind
viru
neutral
mani
bnab
primarili
depend
quaternari
structur
protein
howev
affect
presenc
glycan
peopl
infect
develop
bnab
crossclad
neutral
activ
within
year
infect
control
infect
result
steril
immun
consid
small
fraction
antibodi
elicit
broadli
neutral
function
low
concentr
bnab
vivo
late
occurr
diseas
progress
potenti
differ
approach
gener
bnab
effect
prophylact
vaccin
may
necessari
rais
question
possibl
induc
high
titer
bnab
high
bind
affin
viru
env
immunogen
glycosyl
maintain
conform
protein
one
import
region
env
protein
loop
igg
antibodi
rais
loop
invers
correl
risk
infect
clinic
trial
studi
indic
loop
protein
assum
uniqu
defin
structur
result
high
densiti
glycan
env
protein
effort
subunit
vaccin
develop
use
mammalian
cell
bioproduct
howev
similar
influenza
hemagglutinin
potenti
vaccin
candid
could
develop
antigen
express
e
coli
without
glycosyl
nativelik
conform
induc
high
titer
high
affin
antibodi
could
prevent
initi
infect
use
carrier
may
essenti
develop
success
vaccin
candid
one
technolog
selfassembl
protein
nanoparticl
sapn
sapn
built
coiledcoil
protein
fold
domain
compos
two
glycosyl
env
loop
form
nativelik
structur
may
essenti
nanoparticl
vaccin
choos
correct
combin
coiledcoil
domain
protein
fold
optim
antigen
interest
fold
nativelik
conform
technolog
success
appli
develop
influenza
sar
toxoplasma
malaria
vaccin
candid
immunogen
unglycosyl
although
import
glycosyl
viral
matur
fold
envelop
protein
clear
remain
unclear
proper
glycosyl
level
glycosyl
immunogen
necessari
induc
protect
immun
respons
vaccin
attempt
carri
correl
glycosyl
statu
antigen
immun
respons
hypothes
protect
immun
respons
gener
conform
antibodi
requir
antibodi
gener
properli
fold
immunogen
either
nativ
glycosyl
pattern
display
nanoparticl
carrier
enabl
nativelik
trimer
antigen
conform
produc
subunit
vaccin
candid
mammalian
cell
gener
glycosyl
difficult
yield
tend
lower
cost
tend
higher
glycosyl
pattern
obtain
express
system
may
differ
present
virion
ultim
affect
structur
antigen
use
sapn
technolog
abl
produc
vaccin
candid
e
coli
capabl
rais
high
titer
antibodi
loop
structur
antigen
determin
nativelik
bind
known
conform
antibodi
hypothes
vaccin
unglycosyl
env
antigen
fold
nativelik
confirm
may
gener
function
antibodi
higher
titer
higher
affin
ideal
lead
better
vaccin
candid
valid
hypothesi
studi
requir
compar
function
antibodi
anim
vaccin
unglycosyl
glycosyl
sapn
immunogen
prime
boost
strategi
vaccin
use
unglycosyl
immunogen
follow
glycosyl
immunogen
use
attempt
gener
high
titer
antibodi
recogn
virion
regardless
glycosyl
statu
p
burkhard
interest
compani
alphao
peptid
patent
patent
pend
technolog
author
relev
affili
financi
involv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
apart
disclos
write
assist
util
product
manuscript
work
licens
attributionnoncommercialnoderiv
unport
licens
view
copi
licens
visit
http
